Allergan’s (AGN) International business segment represents the total revenues from the sales of its branded products and aesthetics products outside of US markets.
This segment reported revenues of $737.3 million for 1Q17, which was 9.5% higher than the $673.3 million it reported in 1Q16.
The performances of the franchises in the International segment in 1Q17 were as follows:
- Plastic surgery products include Natrelle breast augmentation products, silicone-filled implants, and saline-filled implants, and breast reconstruction products. This franchise reported revenues of $38.0 million for 1Q17—a 3.2% higher than its $36.8 million during 1Q16.
- The eyecare franchise includes eye care products like Refresh and Restasis for dry eyes, Alphagan, Lumigan, and Combigan for glaucoma, and other eyecare products like Acular LS, Acuvail, Botox, Elestat, and Pred Forte. The franchise reported revenues of $299.5 million for 1Q17—a 2.7% growth as compared to 1Q16.
- This segment’s skincare products include Prevage and SkinMedica range of products. The skincare franchise reported revenues of $2.2 million for 1Q17.
- The facial aesthetics franchise includes revenues from Botox cosmetic products, Juvederm products, and other products including Latisse and Kybella. The facial aesthetics franchise reported revenues of $245.9 million for 1Q17, which was 19.6% higher than the $205.5 million in 1Q16.
Other therapeutics includes Botox products for urologic and neurosciences, Asacol, and Constella products. This franchise reported revenues of $133.9 million for 1Q17—an 8.6% growth as compared to $123.3 million in 1Q16.
To divest risk, investors can consider ETFs like the iShares S&P Global Healthcare ETF (IXJ), which has 2.3% of its total assets in Allergan. IXJ also has 4.4% in Merck (MRK), 1.8% in AstraZeneca (AZN), and 1.8% in Abbott Laboratories (ABT).